Professional consultation ensures the most appropriate product is selected for each individual's clinical needs
Factors such as: Retatrutide dosage Treatment consistency Diet quality Activity levels Metabolic health can have just as much influence on results as the medication itself
& El Aidy, S
The multicenter, randomized, open-label SURMOUNT-5 trial evaluated the efficacy and safety of Lillys tirzepatide, marketed as Zepbound, and Novos semaglutide, marketed as Wegovy, in adults with obesity, or overweight with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea (OSA) or cardiovascular disease, who did not have diabetes
Scientific References TripleHormone-Receptor Agonist Retatrutide for Obesity (Phase 2 Trial)
Heres the typical progression: Starting Dose : 0.25 mg weekly for the first 4 weeks